Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.

Patients must be on treatment with Betaferon or the decision to treat a patient with Betaferon has been made by the attending physician.

Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device.

Written informed consent must be obtained.

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon